Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies



Rating:

Share or cite this content

Citations should be made in the following way:
F. Kanniess (Reinfeld (Holstein), Germany), L. Tamasi (Budapest, Hungary), R. R. Mroz (Bialystok, Poland), P. Bakakos (Athens, Greece), S. Tubis (Wedel, Germany), G. Resler Plat (Madrid, Spain), A. Shavit (Wedel, Germany). Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE). 3729

Member's Comments

No comment yet.

Related content which might interest you: Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017 Time trends in clinical characteristics of patients with severe asthma: data from the Belgian Severe asthma register (BSAR) Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Mepolizumab eligibility in children with severe asthma – do we need paediatric specific criteria? Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Identifying patients with severe allergic asthma who are potentially eligible for omalizumab treatment by EU licence and NICE guidance criteria Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Baseline demographic and clinical profile of patients with and without cardiovascular diseases in the assessment of comorbidities in COPD in european symptomatic subjects from primary care (ACCESS) study Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013 Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2-agonist (LABA) therapy: results from the UK general practice research database (GPRD) Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care Year: 2009 Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018 Year: 2018 Baseline characteristics of severe asthma patients initiating biologic treatment worldwide Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Symptom pattern and treatment for people non-compliant with asthma medication Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care Year: 2005 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015